Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage (DERANO)

NCT04252248 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT04252248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage (DERANO)
Lead sponsor
University Hospital Heidelberg
Phase
Phase 1
Overall status
Terminated
Start date
October 11, 2019
Completion date
June 15, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anogenital cancer, head and neck cancer